BURLINGAME, Calif., Nov. 1, 2011 /PRNewswire/ -- Epitomics, Inc., a California based biotech company, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for its Method for Identifying Differentially Expressed Proteins (application 10/705,109). The Notice allowed 17 claims for detection of differentially expressed proteins in cell samples using libraries of antibodies. This method has several potentially broad applications in the research and drug discovery markets, especially in the field of cancer.
"We are very excited to be granted the claims of this novel method," stated Dr. Guo-Liang Yu, Chief Executive Officer. "This is another step towards building a world class intellectual property estate around our unique and proprietary rabbit monoclonal technology. We look forward to continued success in the development of our technology and patents, and ultimately to providing the best antibodies and solutions to researchers and clinicians."
Epitomics, Inc., an emerging biotechnology company, is dedicated to developing breakthrough monoclonal antibody technology for research and diagnostic applications. The company utilizes a unique and proprietary RabMAb® (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity, specificity and bioactivity both in vitro and in vivo. Epitomics, Inc. is headquartered in Burlingame, California, and operates wholly owned subsidiaries in Hong Kong and Hangzhou, the People's Republic of China. For more information about Epitomics, please visitwww.epitomics.com
SOURCE Epitomics, Inc.